Clinical benefits of systemic amoxicillin/metronidazole may depend on periodontitis severity and patients' age: An exploratory sub-analysis of the ABPARO trial
Please always quote using this URN: urn:nbn:de:bvb:20-opus-226579
- Aim The aim was to identify benefit thresholds for clinical variables. We hypothesize, if variables fall below or exceed these threshold levels, systemic amoxicillin/metronidazole may contribute to reducing progression of periodontitis. Material & Methods This is an explorative per-protocol collective analysis (n = 345) conducted on the placebo-controlled, multi-centre ABPARO trial (ClinicalTrials.gov NCT00707369). Patients received debridement with systemic amoxicillin 500 mg/metronidazole 400 mg (3×/day, 7 days, n = 170) or placebo (n =Aim The aim was to identify benefit thresholds for clinical variables. We hypothesize, if variables fall below or exceed these threshold levels, systemic amoxicillin/metronidazole may contribute to reducing progression of periodontitis. Material & Methods This is an explorative per-protocol collective analysis (n = 345) conducted on the placebo-controlled, multi-centre ABPARO trial (ClinicalTrials.gov NCT00707369). Patients received debridement with systemic amoxicillin 500 mg/metronidazole 400 mg (3×/day, 7 days, n = 170) or placebo (n = 175) and maintenance therapy every three months. To identify thresholds, each of the following baseline characteristics was classified into two groups (≥threshold value/<threshold value): bleeding on probing, extent of pocket probing depth (PPD) ≥ 5 mm, mean clinical attachment level and age. Treatment effect (% of sites with new attachment loss ≥ 1.3 mm at 27.5 months post-treatment) was calculated. Results Adjunctive antimicrobials reduced median new attachment loss in patients < 55 years (5.2%), or with ≥ 35% PPD ≥ 5 mm (4.5%) or with a mean attachment level > 5 mm (5.2%) at baseline compared to the placebo (9.0%, 11.6%, and 12.5%, respectively; p < 0.005). Conclusions The clinical benefits of systemic amoxicillin/metronidazole may depend on periodontitis severity and patients' age.…
Author: | Peter Eickholz, Raphael Koch, Thomas Kocher, Thomas Hoffmann, Ti-Sun Kim, Joerg Meyle, Doğan Kaner, Ulrich Schlagenhauf, Dag Harmsen, Inga Harks, Benjamin Ehmke |
---|---|
URN: | urn:nbn:de:bvb:20-opus-226579 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Abteilung für Parodontologie (in der Poliklinik für Zahnerhaltung und Parodontologie) |
Language: | English |
Parent Title (English): | Journal of Clinical Periodontology |
Year of Completion: | 2019 |
Volume: | 46 |
Pagenumber: | 491-501 |
Source: | Journal of Clinical Periodontology (2019) 46:491-501. https://doi.org/10.1111/jcpe.13096 |
DOI: | https://doi.org/10.1111/jcpe.13096 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | amoxicillin/metronidazole; attachment loss; clinical threshold; periodontitis; systemic antimicrobials |
Release Date: | 2024/09/04 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |